1. Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease
- Author
-
Essam Mohamed Byoumy, Ghada Mahmoud Mohamed, Mohamed Abdallah, Salama Mm, Ahmed I. Elshafie, Wesam A. Ibrahim, and Azza Abd Elhameed Mohamed
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Fatty liver ,nutritional and metabolic diseases ,Adipokine ,Disease ,medicine.disease ,digestive system ,Obesity ,Gastroenterology ,digestive system diseases ,Insulin resistance ,Internal medicine ,medicine ,biology.protein ,Chemerin ,business ,Grading (tumors) ,Serum markers - Abstract
Background: Attempts have been made to recognize noninvasive markers for the identification of non-alcoholic fatty liver disease (NAFLD). Chemerin is a newly defined adipokine linked to insulin resistance and adipogenesis. Objective: This study intended to evaluate the diagnostic ability of serum chemerin compared with NAFLD fibrosis score as a noninvasive marker for the diagnosis and grading of NAFLD. Patients and methods: We enrolled 60 NAFLD patients and categorized them into 3 subgroups based on the fatty liver grade by ultrasound. Thirty healthy participants were recruited as a control group. ELISA method was used for serum chemerin levels measurement. Results: Serum chemerin levels were significantly higher in NAFLD cases than controls (p ≤ 0.001). Furthermore, these levels were positively correlated with the fatty liver grade (p ≤ 0.001). Serum chemerin was comparable to NAFLD fibrosis score as regards NAFLD diagnosis (p ≤ 0.001). Patients within the gray zone of NAFLD fibrosis score had a significantly higher serum chemerin levels in comparison to patients under the gray zone (p ≤ 0.001). Conclusion: Serum chemerin is a promising marker for diagnosing and grading of NAFLD. More research is required to determine its definitive clinical benefit in patients with NAFLD.
- Published
- 2021